Press release
Glucagon-Like Peptide Agonist Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight
Curious about the latest updates in the Glucagon-Like Peptide Agonist Pipeline? Click here to explore the therapies and trials making headlines @ Glucagon-Like Peptide Agonist Pipeline Outlook Report [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Glucagon-Like Peptide Agonist Pipeline Report
* Nov. 30, 2025, Ascletis Pharma Inc. (HKEX: 1672) announced the selection of ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR triple peptide agonist, as the company's latest clinical development candidate. This strategic milestone marks a significant advancement in Ascletis' metabolic disease pipeline. The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 for ASC37 oral tablets, targeting the treatment of obesity.
* DelveInsight's Glucagon-Like Peptide Agonist Pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Glucagon-Like Peptide Agonist treatment.
* The leading Glucagon-Like Peptide Agonist Companies such as Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics and others.
* Promising Glucagon-Like Peptide Agonist Therapies such as Exenatide, NG101 , and others.
Want to know which companies are leading innovation in Glucagon-Like Peptide Agonist? Dive into the full pipeline insights @ Glucagon-Like Peptide Agonist Clinical Trials Assessment [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Glucagon-Like Peptide Agonist Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Glucagon-Like Peptide Agonist Pipeline Report also highlights the unmet needs with respect to the Glucagon-Like Peptide Agonist.
Glucagon-Like Peptide Agonist Overview
Glucagon-Like Peptide (GLP) agonists are a class of medications primarily used in the treatment of type 2 diabetes mellitus. They mimic the action of endogenous GLP-1, a hormone secreted by the intestine in response to food intake. GLP-1 plays a crucial role in regulating glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release, both of which help to lower blood sugar levels. Several types of GLP-1 receptor agonists are available, each with unique formulations and dosing regimens. Exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are among the most commonly prescribed GLP-1 agonists. These medications are typically administered via subcutaneous injection, with dosing frequency ranging from once-daily to once-weekly injections. Such convenience in dosing improves patient adherence and may contribute to better treatment outcomes.
Glucagon-Like Peptide Agonist Emerging Drugs Profile
* Survodutide: Boehringer Ingelheim
Survodutide is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action that activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. Survodutide was co-invented by Boehringer Ingelheim and Zealand Pharma. Survodutide has received US FDA Fast Track Designation as well as a PRIME designation in the EU for the treatment of NASH. Survodutide is being evaluated in Phase III trials for people living with obesity, Non-alcoholic steatohepatitis, and Type 2 diabetes mellitus.
* MK-6024: Merck
MK-6024 is an investigational peptide and dual agonist at glucagon-like peptide 1 (GLP-1) and glucagon receptors in clinical development for the treatment of NASH. MK-6024 is being developed under an exclusive licensing agreement between Merck and Hanmi Pharmaceutical for the treatment of patients with NASH. The drug has been granted Fast Track Designation by the US FDA for the treatment of NASH, a more severe form of NAFLD. A Phase IIa clinical trial was conducted that compared the efficacy and safety of efinopegdutide to the GLP-1 receptor agonist semaglutide in patients with NAFLD. The results of this trial were presented at the 2023 European Association for the Study of the Liver (EASL) Annual Congress. Currently, the drug is in Phase II stage of its development for the treatment of Non-alcoholic steatohepatitis.
* TE-8105: T-E Pharma Holding
TE-8105 is an ultralong-acting human GLP-1 receptor agonist (peptide segment 7-37 of native human GLP-1), in which alanine at position 8 is replaced by 2-aminoisobutyric acid and lysine at position 26 lysine is conjugated with a fatty acid bundle containing 2 long-chain fatty acids, a C16 acid and a C18 diacid. TE-8105 has been compared with semaglutide, which is modified with one C18 diacid at 26 lysine residue, for various effects. Currently the drug is in Phase I/II stage of its clinical development for the treatment of Non-alcoholic steatohepatitis, Obesity, and Type 2 diabetes mellitus.
* CT-996: Roche
CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity. Unlike the endogenous GLP-1 hormone, CT-996 is specifically designed to be a biased GLP-1 receptor agonist that activates cAMP signaling with minimal-to-no beta-arrestin recruitment. These finely-tuned signaling properties are expected to lead to strong glycemic control, significant weight loss and good tolerability. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Obesity & Type 2 diabetes mellitus.
If you're tracking ongoing Glucagon-Like Peptide Agonist Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Glucagon-Like Peptide Agonist Treatment Drugs [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Glucagon-Like Peptide Agonist Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Glucagon-Like Peptide Agonist with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glucagon-Like Peptide Agonist Treatment.
* Glucagon-Like Peptide Agonist Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Glucagon-Like Peptide Agonist Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glucagon-Like Peptide Agonist market.
Glucagon-Like Peptide Agonist Companies
Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics and others.
Glucagon-Like Peptide Agonist Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Glucagon-Like Peptide Agonist Products have been categorized under various Molecule types such as,
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Glucagon-Like Peptide Agonist Pipeline Report covers it all - check it out now @ Glucagon-Like Peptide Agonist Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Glucagon-Like Peptide Agonist Pipeline Report
* Coverage- Global
* Glucagon-Like Peptide Agonist Companies- Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics and others.
* Glucagon-Like Peptide Agonist Therapies- Exenatide, NG101 , and others.
* Glucagon-Like Peptide Agonist Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Glucagon-Like Peptide Agonist Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Glucagon-Like Peptide Agonist Treatment landscape in this detailed analysis @ Glucagon-Like Peptide Agonist Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Glucagon-Like Peptide (GLP) Agonist: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Glucagon-Like Peptide (GLP) Agonist- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Survodutide: Boehringer Ingelheim
* Mid Stage Products (Phase II)
* MK-6024: Merck
* Early Stage Products (Phase I)
* CT-996: Roche
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Inactive Products
* Glucagon-Like Peptide (GLP) Agonist Key Companies
* Glucagon-Like Peptide (GLP) Agonist Key Products
* Glucagon-Like Peptide (GLP) Agonist- Unmet Needs
* Glucagon-Like Peptide (GLP) Agonist- Market Drivers and Barriers
* Glucagon-Like Peptide (GLP) Agonist- Future Perspectives and Conclusion
* Glucagon-Like Peptide (GLP) Agonist Analyst Views
* Glucagon-Like Peptide (GLP) Agonist Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glucagonlike-peptide-agonist-pipeline-drugs-insights-report-2025-promising-drugs-and-moa-innovations-reshape-future-treatment-approaches-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glucagon-like-peptide-glp-agonist-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glucagon-Like Peptide Agonist Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight here
News-ID: 4298641 • Views: …
More Releases from ABNewswire
Luxe Living Home Essentials Brings Elevated Kitchen Solutions to Busy American H …
Luxe Living Home Essentials, a woman-owned lifestyle brand founded by bestselling author Loreitha Lacewell, is transforming everyday cooking with thoughtfully designed kitchen products that balance style, functionality, and affordability. The brand has quickly established itself as a trusted destination for quality home essentials through strategic e-commerce growth and engaging pop-up retail experiences.
Luxe Living Home Essentials is redefining the home and kitchen marketplace with a carefully curated collection of products designed…
The Future of Commercial Hacking and Demolition in Singapore: 2026 Market Trends
Explore key 2026 trends shaping commercial hacking and demolition in Singapore, including market growth, tech innovations, regulations, and opportunities. Visit us today!
Singapore's built environment is constantly being renewed. As commercial properties adapt to new business models, regulatory standards, and sustainability goals, the role of hacking and demolition has become increasingly strategic. What was once viewed as a basic preparatory task is now recognised as a critical phase that determines project…
New Year Resolution Meets Social Impact: Maple and Mocha Coffee Extends Holiday …
Following successful holiday season launch, Maple and Mocha Coffee continues its commitment to the Kyempapu Water Project into the new year. The company's Vermont Maple Pecan blend bridges the gap between holiday indulgence and New Year wellness goals while maintaining its 10% donation pledge to support clean water access in Kirinda village.
The transition from holiday indulgence to New Year wellness traditionally challenges specialty food companies, but Maple and Mocha Coffee…
Truthkins Gives Families a New Way to Tackle Childhood Emotions in the New Year …
As parents set goals for the year ahead, Truthkins offers a hands-on tool for helping children understand and navigate their feelings. Created by Rick Dieterle ("Dee-ter-Lee"), a New Hampshire dad who wanted something better for his own kids, each Truthkins set includes two plush characters representing opposing emotions, a reminder wristband, an illustrated storybook, and a Bible blanket that connects with others to build a collectible mega blanket.
The new year…
More Releases for Peptide
ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in H …
ShiLai Peptide's CEO, Luo Binhua, said the investment reflects the company's commitment to a "new science model" that integrates research-driven development, controlled production, and specialized customer support.
ShiLai Peptide [https://retatrutidesupplier.com/], a leading provider of high-purity, customizable research peptides, announced plans to invest $32 million to build a state-of-the-art peptide research and production laboratory in Hangzhou. The facility is designed to meet world-class GMP standards, aiming to strengthen ShiLai's global supply of…
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
